Global state: 2. Clinically important change (no improvement) ‐ long term · schizophrenia
It is very uncertain whether haloperidol discontinuation changes global state: clinically important change ‒ not improved (CGI) compared with haloperidol continuation (very low certainty).
1 finding from 1 review
Relapse · schizophrenia
It is very uncertain whether haloperidol discontinuation changes global state: relapse: ‒ compared with haloperidol continuation (very low certainty).
1 finding from 1 review
Mental state: clinically important change in mental state · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
General functioning: clinically important change in general functioning including working ability · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Behaviour: clinically important change in general behaviour · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life: clinically important change in quality of life · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Satisfaction with treatment: leaving the study early Endpoint data (events) · schizophrenia
It is very uncertain whether haloperidol discontinuation changes satisfaction with treatment: leaving the study early compared with haloperidol continuation (very low certainty).
1 finding from 1 review
Adverse events: Serious event or requiring discontinuation · schizophrenia or related disorders
It is very uncertain whether combinations of antipsychotic drugs changes adverse events: Serious event or requiring discontinuation compared with single antipsychotic drugs (very low certainty).
1 finding from 1 review
Global: Discontinuation of Vitamin B6 · patients with antipsychotic‐induced tardive dyskinesia
Pyridoxal 5 phosphate (vitamin B6) showed no clear difference in global: Discontinuation of Vitamin B6 compared with placebo (low certainty).
1 finding from 1 review